Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Melanoma mystery solved? 232 patient records reveal clues to better treatment

NCT ID NCT07256184

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at the medical records of 232 adults with advanced melanoma to find out which factors—like patient traits, tumor features, and treatments—are linked to better outcomes. Researchers reviewed data from people treated between 2022 and 2024 at hospitals in Türkiye. The goal is to use this real-world information to help doctors choose the best treatment for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

232 people

The number who actually took part.

Started

Nov 2022

Finished

Dec 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with metastatic malignant melanoma treated with standard systemic therapy, including immune checkpoint inhibitors, BRAF/MEK inhibitors, or chemotherapy. Data were extracted retrospectively from electronic medical records across multiple oncology centers in Türkiye.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Histologically or cytologically confirmed metastatic malignant melanoma * Received ≥1 line of systemic therapy * Complete baseline and follow-up data * At least one measurable lesion or clinical response assessment * Managed between November 2022 - December 2024 at participating centers Exclusion Criteria: * Incomplete clinical or pathological data * Uncertain or revised diagnosis * Metastasis developing outside the inclusion window * Another primary malignancy (except allowed types) * Lost to follow-up before first response assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic malignant melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic malignant melanoma

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

  • Gazi University, Medical Oncology Department

    Ankara, Çankaya, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.